Key result
Standing SBP ≥140 mm Hg, but not systolic orthostatic increases, was associated with a higher risk of cardiovascular disease outcomes and death over 30 years.
Why the study?
Recent consensus statements combine a blood pressure rise upon standing with standing hypertension, but whether these two components carry similar cardiovascular disease risk associations was unknown.
Are systolic orthostatic increases and elevated standing SBP associated with incident cardiovascular disease and mortality in adults without baseline CVD?
Cohort (n=11,369)
Yes
Are systolic orthostatic increases and elevated standing SBP associated with incident cardiovascular disease and mortality in adults without baseline CVD?
Elevated standing SBP, but not systolic orthostatic increase, is strongly associated with long-term cardiovascular disease outcomes and mortality, challenging current consensus definitions that combine the two.
Answers are grounded in this paper and cite their sources.
Elevated standing SBP may identify higher-risk adults for monitoring; challenges combined orthostatic definitions but leaves open need for prospective validation.
BACKGROUND: Orthostatic hypertension is an emerging risk factor for adverse events. Recent consensus statements combine an increase in blood pressure upon standing with standing hypertension, but whether these 2 components have similar risk associations with cardiovascular disease (CVD) is unknown. METHODS: The ARIC study (Atherosclerosis Risk in Communities) measured supine and standing blood pressure during visit 1 (1987-1989). We defined systolic orthostatic increase (a rise in systolic blood pressure [SBP] ≥20 mm Hg, standing minus supine blood pressure) and elevated standing SBP (standing SBP ≥140 mm Hg) to examine the new consensus statement definition (rise in SBP ≥20 mm Hg and standing SBP ≥140 mm Hg). We used Cox regression to examine associations with incident coronary heart disease, heart failure, stroke, fatal coronary heart disease, and all-cause mortality. RESULTS: Of 11 369 participants (56% female; 25% Black adults; mean age, 54 years) without CVD at baseline, 1.8% had systolic orthostatic increases, 20.1% had standing SBP ≥140 mm Hg, and 1.3% had systolic orthostatic increases with standing SBP ≥140 mm Hg. During up to 30 years of follow-up, orthostatic increases were not significantly associated with any of the adverse outcomes of interest, while standing SBP ≥140 mm Hg was significantly associated with all end points. In joint models comparing systolic orthostatic increases and standing SBP ≥140 mm Hg, standing SBP ≥140 mm Hg was significantly associated with a higher risk of CVD, and associations differed significantly from systolic orthostatic increases. CONCLUSIONS: Unlike systolic orthostatic increases, standing SBP ≥140 mm Hg was strongly associated with CVD outcomes and death. These differences in CVD risk raise important concerns about combining systolic orthostatic increases and standing SBP ≥140 mm Hg in a consensus definition for orthostatic hypertension.
No takes yet. Share an insight, caveat, or question.
Dooley et al. (2024) conducted a cohort in Without cardiovascular disease (n=11,369). Standing SBP ≥140 mm Hg and systolic orthostatic increase was evaluated on Incident coronary heart disease, heart failure, stroke, fatal coronary heart disease, and all-cause mortality. Standing SBP ≥140 mm Hg, but not systolic orthostatic increases, was associated with a higher risk of cardiovascular disease outcomes and death over 30 years.
Synapse has enriched 10 related papers. Consider them for comparative context: